- recruitingTherapeutic confirmatory (Phase III)
B7981040 - A PHASE 3 RANDOMIZED, DOUBLE-BLIND, 52-WEEK PLACEBOCONTROLLED, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY, SAFETY, AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO
This study is testing a new medicine, Ritlecitinib, for vitiligo, a skin condition where you lose skin colour. It aims to see how well it works and if it's safe for adults and teenagers.
Bulgaria · Spain · Germany - recruitingTherapeutic exploratory (Phase II)
A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MK-6194 in Adult Participants with Non-Segmental Vitiligo.
This study is testing a new medicine, MK-6194, for adults with a type of vitiligo called non-segmental vitiligo. Researchers want to see if the medicine can help reduce white patches on the face and if it's safe to use, compared to a dummy medicine.
Belgium · Germany · Spain